芬吗通治疗围绝经期综合征的效果

Effect of Femoston in the treatment of perimenopausal syndrome

目的探讨芬吗通(1/10)连续序贯治疗围绝经期综合征的临床效果及对患者血清中性激素和血脂的影响及安全性。方法回顾性分析2014年1月~2016年12月在北京航天总医院妇科门诊治疗的150例围绝经期综合征患者的临床资料,根据治疗方法的不同分为对照组(n=70)和观察组(n=80)。对照组患者采用戊酸雌二醇片/黄体酮胶丸周期序贯治疗,观察组患者采用芬吗通连续序贯治疗,连续治疗6个周期。治疗前后采用女性更年期综合征自我诊断评定表评估患者更年期症状的严重程度,比较两组患者的卵泡刺激素(FSH)、雌二醇(E2)、血脂水平及子宫内膜厚度等。结果治疗后,两组血清FSH水平均较治疗前明显降低(P<0.05),血清E2水平较治疗前明显升高,且观察组血清E2水平高于对照组(P<0.05)。治疗后,两组患者的Kupperman评分低于治疗前(P<0.05),且观察组Kupperman评分明显低于对照组(P<0.05)。两组治疗前后血脂、体重指数、血压水平比较,差异无统计学意义(P>0.05);两组治疗后血脂、体重指数、血压水平比较,差异无统计学意义(P>0.05)。服药6个周期后,两组患者未见明显不良反应。结论芬吗通(1/10)能有效治疗女性更年期症状,较好地调节月经周期和内分泌水平,无子宫内膜过度刺激,具有服用方便、依从性好的优点。

Objective To investigate clinical effect and safety of Femostone （1/10） corisecutive sequential treatment of perimenopausal syndrome. Methods Clinical data of 150 patients with perimenopausal syndrome treated in outpatient of Beijing Aerospace General Hospital from January 2014 to December 2016 were retrospectively analyzed, according to the treatment of patients, they were divided into control group （n=70） and observation group （n=80）. Patients in con- trol group was treated with cycle sequential treatment of Estradiol Valerate Tablets and Progestin Capsules, observation group was treated with Femostone for 6 months. The severity of female climacteric syndrome before and after treatment was evaluated by Kupperman score, levels of Follicle-stimulating hormone （FSH）, estradiol （E2）, serum lipid and en- dometrial thickness of patients in two groups were tested and compared. Results After treatment, the serum FSH levels in two groups were significantly lower than those before treatment （P 〈 0.05）, E2 levels in two groups were significantly higher than those before treatment, serum E2 level of observation group was higher than that of control group （P 〈 0.05）. After treatment, Kupperman scores in two groups were significantly lower than those before treatment （P 〈 0.05）, obser- vation group was higher than control group （P 〈 0.05）. Blood lipid, body mass index and blood pressure before and after treatment in two groups were compared, with no statistical difference （P 〉 0.05）. Blood lipid, body mass index and blood pressure after treatment in two groups were compared, with no statistical difference （P 〉 0.05）. After 6 months of treatment, there was no obvious side effects in two groups. Conclusion Femostone （1/10） is effective in the treatment of symptoms of menopause, it can control the menstrual cycle and the level of endocrine, without excessive endometrial stimulation, and has the advantages of easy taking and good adherence.